Evaxion’s AI-Immunology™ Platform Expands to Glioblastoma with ERV-Derived Antigens
Event summary
- Evaxion’s AI-Immunology™ platform identified ERV-derived antigens in glioblastoma tumors, expanding its vaccine design capabilities.
- Collaboration with Duke University School of Medicine confirmed the platform’s scalability across different cancer types.
- Data will be presented at the AACR Annual Meeting on April 22, 2026.
- ERV-derived antigens offer a novel target source for glioblastoma vaccines, addressing low mutational burden limitations.
The big picture
Evaxion’s expansion into glioblastoma highlights the growing role of AI in cancer vaccine development, particularly for tumors with low mutational burden. The collaboration with Duke University underscores the platform’s versatility, positioning Evaxion as a key player in the personalized medicine space. Success in this area could drive partnerships and accelerate the adoption of AI-driven immunology solutions.
What we're watching
- Platform Scalability
- How Evaxion will leverage AI-Immunology™ across additional cancer types and diseases.
- Clinical Validation
- The pace at which ERV-derived antigen vaccines progress through clinical trials.
- Partnership Dynamics
- Whether collaborations with academic institutions accelerate glioblastoma vaccine development.
Related topics